The Company proposes to spin-off and separately list the shares of Dermavon, a subsidiary of the Company, on the Main Board of the Stock Exchange. The Proposed Spin-off, if proceeded, is expected to be implemented through a distribution in specie by the Company of all the shares in Dermavon that it holds to the Shareholders in proportion to their respective shareholding in the Company as of a record date to be determined by the Board for the purpose of ascertaining the Shareholders’ entitlements. The separate listing of the shares of Dermavon on the Stock Exchange constitutes a spin-off of Dermavon by the Company under the Practice Note 15 to the Listing Rules. The Stock Exchange has confirmed that the Company may proceed with the Proposed Spin-off. In connection with the Proposed Spin-off, on 22 April 2025, Dermavon submitted an application to the Stock Exchange for the listing of, and permission […]
On April 15, 2025, S&P Global officially released the Sustainability Yearbook (China Edition) 2025. China Medical System Holdings Limited (“CMS” or the “Group”) has stood out among over 1,600 Chinese companies with its outstanding performance in environmental, social, and governance (ESG) practices, marking its third consecutive year of inclusion in the Yearbook. Source: S&P Global CMS has been implementing the concept of sustainable development into its strategy formulation and daily operation, focusing on unmet healthcare needs to provide better treatment solutions for doctors and patients, and striving to improve the accessibility and affordability of pharmaceutical products. At the same time, the Group has been continuously optimizing its internal governance, upholding the bottom line of product responsibility, respecting and empowering employees, and actively participating in public welfare, charity, and environmental protection activities, thus promoting a virtuous cycle of corporate development and responsibility fulfillment. Through persistent dedication to sustainable development, […]
China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that innovative drug CMS-D003 capsules (“CMS-D003”) self-developed by the Group has been granted approval for drug clinical trials by National Medical Products Administration of the People’s Republic of China (“NMPA”) on 11 March 2025. The approval was obtained on 12 March 2025. The NMPA grants the Group consent to conduct a clinical trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of CMS-D003 in both healthy adults and adult patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in China. CMS-D003 CMS-D003 is a small molecule cardiac myosin inhibitor, which is a targeted therapy for hypertrophic cardiomyopathy. By targeting inhibition of cardiac myosin adenosine triphosphate (ATP) enzymes, it inhibits myosin-actin interactions, reduces myofilament sliding, inhibits myocardial over-contraction, and improves diastolic dysfunction of the heart, thereby alleviating the patient’s clinical symptoms[1]. CMS-D003 demonstrates a short half-life, minimal risk for drug […]
In February 11th 2025, with a Corporate Sustainability Assessment (CSA) score of 61, surpassing 93% of global peers, China Medical System Holdings Limited (“CMS” or the “Group”) has been included in the S&P Global Sustainability Yearbook 2025 (the “Yearbook 2025”). This marks the Group’s first inclusion in the global edition of S&P Global Sustainability Yearbook (the “Yearbook”), following the S&P Global Sustainability Yearbook (China Edition) inclusion for consecutive two years. Source: S&P Global Since its launch in 2008, the Yearbook’s professionalism and authority have been highly recognized by global ESG investors and other stakeholders. The Yearbook aims to identify outstanding companies in sustainable development from each industry. 7,690 companies across 62 industries were assessed, while only 780 stood out and were included in the Yearbook 2025. The inclusion in the Yearbook 2025 represents a high recognition of sustainable development practices of CMS. CMS has been actively responding […]
China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) is pleased to announce that on 24 January 2025, the Group through subsidiaries of the Company entered into a Collaboration Agreement with Hunan Mabgeek Biotechnology Co., Ltd. (“Mabgeek Biotechnology”) and its subsidiary for Class 1 innovative drug anti-IL-4Rα humanized monoclonal antibody injection MG-K10 (“MG-K10” or the “Product”). The Group has obtained the co-development right as specifically agreed upon in the Agreement and exclusive commercialization right to the Product in Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region, Taiwan Region and Singapore (the “Territory”); Mabgeek Biotechnology will support the commercialization activities and is responsible for the sale and supply of the Product. The collaboration term is perpetual. IL-4Rα is considered a key target for the treatment of type 2 inflammatory diseases, such as atopic dermatitis (AD), asthma, prurigo nodularis, etc. Anti-IL-4Rα monoclonal […]
On 7 January 2025, a magnitude 6.8 earthquake, which struck at a depth of 10 km, hit Tingri County, Shigatse City in Tibet, causing heavy casualties and house damages. Caring about the disaster, China Medical System Holdings Limited (“CMS”) has made proactive disaster relief efforts through its wholly-owned subsidiary, Tibet Kangzhe Pharmaceutical Development Co., Ltd. On January 9th, it donated relief supplies worth nearly RMB 0.5 million to the earthquake-stricken area through Tibet Development Philanthropic Foundation, including disinfectant, military coats, cotton quilts, and cotton jackets, etc. Moreover, on January 13th, it donated a special fund of RMB2 million to Tibet Charity Federation for post-disaster resettlement and reconstruction, to further help the disaster area to overcome the difficulties sooner. Join hands to fight the disaster, and pray for peace and safety. CMS wishes the earthquake-stricken area in Shigatse, Tibet rebuild their homes as earlier as possible.
China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) is pleased to announce that on 8 January 2025, the Group through a wholly-owned subsidiary of the Company entered into a License, Collaboration and Distribution Agreement (the “Agreement”) with Alpha Cognition Inc. (“Alpha”) of the improved new drug ZUNVEYL（benzgalantamine delayed-release tablets）(“ZUNVEY” or the “Product”) for the treatment of mild-to-moderate dementia of the Alzheimer’s type. The Group is entitled to an exclusive right to develop, register, manufacture, import, export and commercialize the Product in Asia (excluding Japan and the Middle East), Australia and New Zealand (the “Territory”), Alpha reserves the right to manufacture and supply in the Territory. The term of cooperation commences on the effective date of the Agreement and extends for twenty years, which may be automatically renewed every five years upon the expiration unless terminated by notice from either party. As the […]
On 6 December, China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that the first prescriptions for the innovative drug Lumeblue® (Methylthioninium Chloride Enteric-coated Sustained-release Tablets) (the “Product”) have been issued in China, which marks that the first oral methylthioninium chloride enteric-coated sustained-release tablets in China has officially entered clinical application. The Product is indicated for enhancing visualization of colorectal lesions in adult patients undergoing screening or surveillance colonoscopies. Lumeblue® is an oral diagnostic drug that uses patented multi-matrix (MMXTM) technology to deliver active substances directly to the colon and release them locally in a controlled manner. As an enhancer dye, the Product increases the contrast between colorectal lesions and healthy mucosa. The results of the Phase III clinical trial in China show that the Product can significantly improve the detection rate of non-polypoid colorectal lesions (the primary endpoint of the study), leading to an improved detection rate of dangerous lesions such as non-polypoid adenomas […]
China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) is pleased to announce that on 2 December 2024, the Group through a wholly-owned subsidiary of the Company entered into an Exclusive Commercialization Agreement (the “Agreement”) with Atom Therapeutics Co., Ltd (hereinafter referred to as “Atom Therapeutics”, formerly named as “Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.”) of class 1 innovative drug ABP-671 for the treatment of gout and hyperuricemia (the “Product”). In accordance with the Agreement, the Group is entitled to an exclusive commercialization right of the Product in Mainland China, Hong Kong Special Administrative Region and Macao Special Administrative Region. The term of cooperation commences on the effective date of the Agreement and extends for ten years from the date the Product is first approved for market launch in Mainland China (the “Authorization Term”). Upon the expiration of the Authorization Term, it may be automatically renewed for an additional ten years, […]
China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that innovative drug CMS-D005 injection (“CMS-D005”) self-developed by the Group has been granted approval for drug clinical trials by National Medical Products Administration of the People’s Republic of China (“NMPA”) on 27 November 2024. The NMPA grants the Group consent to conduct a clinical trial to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic profile of CMS-D005 in healthy and overweight/obese adult subjects in China. CMS-D005 CMS-D005 is a highly active and selective dual agonist of glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR). Activating glucagon-like peptide-1 (GLP-1) can reduce food intake through central appetite suppression and inhibit gastric emptying to increase satiety to achieve weight loss. Activating GLP-1R can enhance secretion of glucose-dependent insulin and inhibit secretion of glucagon to lower blood glucagon[1], while activating glucagon (GCG) can promote fat catabolism and enhance fat loss, […]
